| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1919-10-26 |
| Identifiers | MRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063 |
| Document date | 2026-11-01 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection. Concerns: Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital; Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2002-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2003-02-10 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Diagnostic mammography of both breasts: 1.9 cm irregular, spiculated retroareolar mass in the right breast (BI-RADS 5); left breast with no mass or gynecomastia (BI-RADS 1) | 2002-09-16 to 2002-09-16 | completed | S |
| Ultrasound of both breasts and both axillae: 1.8 cm irregular hypoechoic retroareolar mass in the right breast; one right axillary lymph node with a thickened cortex; left breast and left axilla normal | 2002-09-16 to 2002-09-16 | completed | S |
| Ultrasound-guided core needle biopsy of the right breast mass and the right axillary node: invasive ductal carcinoma, grade 2; estrogen receptor 95 percent, progesterone receptor 80 percent, HER2 1+ (negative), Ki-67 15 percent; the node contains metastatic carcinoma | 2002-09-18 to 2002-09-18 | completed | S |
| Bilateral mastectomy, at another hospital. Pathology: right breast, invasive ductal carcinoma 1.8 cm, grade 2, margins clear, no lymphovascular invasion; left breast, benign breast tissue | 2002-10-07 to 2002-10-07 | completed | S |
| Right axillary lymph node dissection, at the same operation: 1 of 14 lymph nodes with a 4 mm metastasis, no extranodal extension; pT1c pN1a, stage IIA | 2002-10-07 to 2002-10-07 | completed | S |
| Advance care planning conversation, about 20 minutes | 2003-10-13 to 2003-10-13 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2002-10-14 | High-dose influenza vaccine, 2002-2003 season | completed | S |
| 1995-04-10 | Tdap vaccine | completed | S |
| 2003-10-13 | High-dose influenza vaccine, 2003-2004 season | completed | S |
| 2003-10-13 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2003-10-13 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| September 2002 | Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor before | D (CLM-0003) |
| 2002 | Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spread | D (CLM-0004, CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital | active | S |
| Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.8 on 2003-01-13; Leukocytes [#/volume] in Blood by Automated count 6.1 on 2003-01-13; Platelets [#/volume] in Blood by Automated count 214 on 2003-01-13; Sodium [Moles/volume] in Serum or Plasma 140 on 2003-01-13; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2003-01-13; Creatinine [Mass/volume] in Serum or Plasma 1.04 on 2003-01-13; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M 71 on 2003-01-13; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2003-01-13; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2003-01-13; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 2003-01-13; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 76 on 2003-01-13; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2003-01-13; Albumin [Mass/volume] in Serum or Plasma 4 on 2003-01-13; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 2003-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2003-01-13; DXA Femur [T-score] Bone density -1.2 on 2003-02-10; DXA Lumbar spine [T-score] Bone density -0.4 on 2003-02-10; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2003-10-13; Total score [Mini-Cog] 5 on 2003-10-13; Total score [AUDIT-C] 0 on 2003-10-13; Cholesterol [Mass/volume] in Serum or Plasma 176 on 2003-10-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2003-10-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 on 2003-10-13; Triglyceride [Mass/volume] in Serum or Plasma 92 on 2003-10-13 [S]
Strengths and supports: Supports: family and a wide circle of friends and former colleagues [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2003-01-13 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2003-01-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2003-01-13 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2003-01-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2003-01-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2003-01-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2003-01-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M | 71 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2003-01-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2003-01-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-55 U/L | Normal | S |
| 2003-01-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 2003-01-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 76 | U/L | 40-129 U/L | Normal | S |
| 2003-01-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2003-01-13 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2003-01-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 2003-01-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2003-02-10 | DXA Femur [T-score] Bone density | -1.2 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2003-02-10 | DXA Lumbar spine [T-score] Bone density | -0.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2003-02-10 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2003-05-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 2003-05-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2003-08-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2003-10-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2003-10-13 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2003-10-13 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2003-10-13 | Cholesterol [Mass/volume] in Serum or Plasma | 176 | mg/dL | <=200 mg/dL | Normal | S |
| 2003-10-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2003-10-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 | mg/dL | <=129 mg/dL | Normal | S |
| 2003-10-13 | Triglyceride [Mass/volume] in Serum or Plasma | 92 | mg/dL | <=149 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2003-01-13 | Body height | 183 | cm | S |
| 2003-01-13 | Body weight | 81.6 | kg | S |
| 2003-01-13 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2003-01-13 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2003-01-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2003-01-13 | Heart rate | 70 | /min | S |
| 2003-01-13 | Respiratory rate | 14 | /min | S |
| 2003-01-13 | Body temperature | 36.6 | Cel | S |
| 2003-01-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2003-02-10 | Body height | 183 | cm | S |
| 2003-02-10 | Body weight | 81.8 | kg | S |
| 2003-02-10 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2003-02-10 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2003-02-10 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2003-02-10 | Heart rate | 68 | /min | S |
| 2003-02-10 | Respiratory rate | 14 | /min | S |
| 2003-02-10 | Body temperature | 36.7 | Cel | S |
| 2003-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2003-05-12 | Body height | 183 | cm | S |
| 2003-05-12 | Body weight | 82.2 | kg | S |
| 2003-05-12 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2003-05-12 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2003-05-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2003-05-12 | Heart rate | 66 | /min | S |
| 2003-05-12 | Respiratory rate | 14 | /min | S |
| 2003-05-12 | Body temperature | 36.6 | Cel | S |
| 2003-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2003-08-11 | Body height | 183 | cm | S |
| 2003-08-11 | Body weight | 82 | kg | S |
| 2003-08-11 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2003-08-11 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2003-08-11 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2003-08-11 | Heart rate | 68 | /min | S |
| 2003-08-11 | Respiratory rate | 14 | /min | S |
| 2003-08-11 | Body temperature | 36.7 | Cel | S |
| 2003-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2003-10-13 | Body height | 183 | cm | S |
| 2003-10-13 | Body weight | 82.4 | kg | S |
| 2003-10-13 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2003-10-13 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2003-10-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2003-10-13 | Heart rate | 68 | /min | S |
| 2003-10-13 | Respiratory rate | 14 | /min | S |
| 2003-10-13 | Body temperature | 36.6 | Cel | S |
| 2003-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2003-01-13 | First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection | finished | S |
| 2003-02-10 | Four-week follow-up with medical oncology consultation: adjuvant plan, germline testing, tamoxifen safety, and bone density results | finished | S |
| 2003-05-12 | Three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheck | finished | S |
| 2003-08-11 | Survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care plan | finished | S |
| 2003-10-13 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Medical oncology consultation to take over adjuvant endocrine therapy, confirm that no further adjuvant treatment is needed, and arrange germline genetic testing | completed | GL-ASCO-MBC-2020, GL-NCCN-BREAST-2025 | S |
| Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visit | completed | GL-ASCO-MBC-2020, GL-CMID-2026 | S |
| Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the result | completed | GL-ASCO-MBC-2020, GL-ASCO-SSO-GERM-2024 | S |
| Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrence | completed | GL-ASCO-MBC-2020, GL-ASCO-BONE-2019, GL-CMID-2026 | S |
| Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checks | completed | GL-CMID-2026, GL-ACS-ASCO-SURV-2016, GL-ASCO-MBC-2020 | S |
| Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plan | completed | GL-ACS-ASCO-SURV-2016, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Take tamoxifen every day with side effects managed, aiming to continue for at least five years | 2003-08-11 | completed | No missed doses by pill count over seven months; mild hot flashes and a mild fall in libido, both manageable; no clot symptoms | S |
| Complete germline genetic testing with counseling, and give him written information for his relatives | 2003-05-12 | completed | No pathogenic variant in a multigene panel; family letter given | S |
| Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise | 2003-05-12 | completed | Femoral neck T-score -1.2; vitamin D 36 ng/mL after supplementation | S |
| Give a written survivorship care plan with the surveillance schedule | 2003-08-11 | completed | Survivorship care plan given at the survivorship visit | S |